

Product Name: GW 843682X

Catalog No.: 2977

Batch No.: 2

CAS Number: 660868-91-7

IUPAC Name: 5-(5,6-Dimethoxy-1*H*-benzimidazol-1-yl)-3-[[2-(trifluoromethyl)phenyl]methoxy]-2-thiophenecarboxamide

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: C₂₂H₁₈F₃N₃O₄S·½H₂O


Batch Molecular Weight: 481.96

Physical Appearance: Pale yellow solid

Solubility: DMSO to 75 mM
ethanol to 5 mM

Storage: Desiccate at +4°C

Batch Molecular Structure:



2. ANALYTICAL DATA

TLC: R_f = 0.33 (Dichloromethane:Methanol [9:1])

HPLC: Shows 98.4% purity

¹H NMR: Consistent with structure

Mass Spectrum: Consistent with structure

Microanalysis:

	Carbon	Hydrogen	Nitrogen
Theoretical	54.83	3.87	8.72
Found	54.75	3.51	8.32

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

bio-techne.com

info@bio-techne.com

techsupport@bio-techne.com

North America

Tel: (800) 343 7475

China

info.cn@bio-techne.com

Tel: +86 (21) 52380373

Europe Middle East Africa

Tel: +44 (0)1235 529449

Rest of World

www.tocris.com/distributors

Tel: +1 612 379 2956

Product Name: GW 843682X

Catalog No.: 2977

2

CAS Number: 660868-91-7

IUPAC Name: 5-(5,6-Dimethoxy-1*H*-benzimidazol-1-yl)-3-[[2-(trifluoromethyl)phenyl]methoxy]-2-thiophenecarboxamide

Description:

GW 843682X is a selective inhibitor of polo-like kinase 1 (PLK1) and polo-like kinase 3 (PLK3) (IC₅₀ values are 2.2 and 9.1 nM respectively). Displays > 100-fold selectivity over ~30 other kinases tested including cdk1 and cdk2. Inhibits proliferation of most tumor cells in vitro and is selective over normal diploid fibroblasts.

Physical and Chemical Properties:


Batch Molecular Formula: C₂₂H₁₈F₃N₃O₄S.¼H₂O

Batch Molecular Weight: 481.96

Physical Appearance: Pale yellow solid

Minimum Purity: ≥98%

Batch Molecular Structure:



Storage: Desiccate at +4°C

Solubility & Usage Info:

DMSO to 75 mM

ethanol to 5 mM

When purchased as a 1mg unit, this product is supplied in lyophilized form. It may appear as a solid, gel or film and be very hard to visualize. Solutions should be made by adding solvent directly to the vial. The vial should then be vortexed vigorously to ensure the product has completely dissolved.

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. *Unless contradicted by product-specific protocols or instructions, our standard recommendations apply:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

Licensing Information:

Sold for research purposes under agreement from GlaxoSmithKline

References:

Lansing et al (2007) *In vitro* biological activity of a novel small-molecule inhibitor of polo-like kinase 1. *Mol.Cancer Ther.* **6** 450. PMID: 17267659.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

bio-techne.com

info@bio-techne.com

techsupport@bio-techne.com

North America

Tel: (800) 343 7475

China

info.cn@bio-techne.com

Tel: +86 (21) 52380373

Europe Middle East Africa

Tel: +44 (0)1235 529449

Rest of World

www.tocris.com/distributors

Tel:+1 612 379 2956